REGENXBIO Inc. (RGNX)

16,83 +0,19 (+1,14%) Alla chiusura: 04:00PM EDT

REGENXBIO Inc.

9804 Medical Center Drive
Rockville, MD 20850
United States
240 552 8181
https://www.regenxbio.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 344

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Kenneth T. Mills	President, CEO & Director	1M	720,99k	1975
Mr. Vittal K. Vasista	Executive VP & CFO	666,5k	573,3k	1968
Mr. Curran M. Simpson M.S.	Executive VP & COO	698,6k	N/D	1962
Dr. Olivier Danos Ph.D.	Executive VP & Chief Scientific Officer	778,85k	N/D	1958
Dr. Stephen Pakola M.D.	Executive VP & Chief Medical Officer	674,05k	N/D	1969
Mr. Patrick J. Christmas II, J.D.	Executive VP & Chief Legal Officer	1,11M	1,29M	1971
Ms. Shiva G. Fritsch	Chief Communications & People Officer	N/D	N/D	N/D
Dr. Laura A. Coruzzi J.D., Ph.D.	Executive Vice President of Intellectual Property	N/D	N/D	1954
Dr. Ram Palanki Pharm.D.	Executive VP of Commercial Strategy & Operations	N/D	N/D	1976

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Governance aziendale

L'ISS Governance QualityScore di REGENXBIO Inc. al 1 maggio 2024 è 8. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 8; diritti degli azionisti: 8; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.